Tenx Keane Acquisition  (TENKU)
Other Ticker:  
Price: $12.0000 $-0.61 -4.837%
Day's High: $12 Week Perf: 0.59 %
Day's Low: $ 12.00 30 Day Perf: 9.39 %
Volume (M): 0 52 Wk High: $ 12.61
Volume (M$): $ 1 52 Wk Avg: $10.99
Open: $12.00 52 Wk Low: $10.53

 Market Capitalization (Millions $) 79
 Shares Outstanding (Millions) 7
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 1
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Tenx Keane Acquisition
Tenx Keane Acquisition is a merger between Tenx Capital, a private equity firm, and Keane, a leading provider of comprehensive solutions for unclaimed property compliance and investigations. The acquisition aims to combine their respective expertise and resources to create a stronger entity in the unclaimed property industry.

Tenx Capital brings its financial expertise and capital resources to the partnership, while Keane brings its extensive experience and established presence in the field of unclaimed property compliance. Through this merger, the companies seek to expand their capabilities, enhance their service offerings, and create a larger market presence.

The acquisition is expected to drive growth for both parties by leveraging their synergies and expanding their customer base. It also offers an opportunity to develop innovative solutions and advanced technologies to better serve clients in managing and resolving unclaimed property obligations.

Overall, the Tenx Keane Acquisition aims to create a market leader in the unclaimed property industry by combining the strengths and capabilities of Tenx Capital and Keane.

   Company Address: 420 Lexington Avenue New York 10170 NY
   Company Phone Number: 627-0058   Stock Exchange / Ticker: NASDAQ TENKU


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Enveric Biosciences Inc

Among many businesses, the ENVB issued also its first quarter of 2024 effort

Following the leaders in the Major Pharmaceutical Preparations industry, some lesser known businesses are publishing their results. ENVB told it has announced operating loss of $-2.477317 million, for the first quarter of 2024.

Nexien Biopharma Inc

The company released operating shortfall of $-0.015947 million, in the January to March 31 2024

The shareholders have not anticipated any modifications at the business during the the earnings cycle of fiscal January to March 31 2024 at the company. However, they monitor NXENs' operating shortfall that has been at $-0.015947 million, in the same period.

Evofem Biosciences Inc

revenue have tumbled at Evofem Biosciences Inc in the fiscal period closing Mar 31 2024

Evofem Biosciences Inc reported disappointing fiscal period closing Mar 31 2024, where Revenue melted down by -37.976 % to $3.60 million and the Major Pharmaceutical Preparations company posted net deficit per share to $-0.16, in proportion to $-1.85, in the fiscal period ending March 31 2023.

Abeona Therapeutics Inc

The Major Pharmaceutical Preparations company has failed to turn into profitability in spite of epic Surge in revenue at the Abeona Therapeutics Inc amid the financial period ending March 31 2024

ABEO announced very solid Revenue elevation of 131.593 % year on year to $0.84 million in the financial period ending March 31 2024, but increased a loss per share at $-1.16. ABEOs' withstands theMajor Pharmaceutical Preparations industries momentum and reports top-line improvement , as virtually all of the Major Pharmaceutical Preparations industry contemporaries, stand at revenue decline during the matching period.

Anebulo Pharmaceuticals Inc

In the financial period ending third quarter of 2024 operating shortfall illustrated progress to $-2.864041 million, at the Major Pharmaceutical Preparations company

The investors did not expect some changes at the top-line throughout the the January to March 31 2024 reporting season at the company. But, they monitor ANEBs' operating shortfall that came in at $-1.664251 million, in the same period.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com